Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: For poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), American Joint Committee on Cancer (AJCC) recommends to use a classification different from that for well-differentiated neuroendocrine tumor. However, this is not adopted by European Neuroendocrine Tumor Society (ENETS) staging classification.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Zhang Y, Chen L, Lin Z, Zhang T, Chen M,
Keywords: gastroenteropancreatic neuroendocrine carcinoma, prognosis, staging,
Introduction: Rectal neuroendocrine carcinomas (NEC) are extremely rare and account for less than 1% of colorectal malignancies.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Della Torre S
Authors: Lombardi P, Grandi S, Marinelli M, Manara M, Della Torre S,
Keywords: rectal nec, net, chemotherapy, metastatic disease,
Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Li Y, Tan H, Jie C, Jie L, Pan Z,
Keywords: clinicopathological features, prognostic analysis, well-differentiated gastric neuroendocrine tumors, grade, type,
Introduction: Carboplatin-Etoposide is a first-line option for patients (pts) with advanced EP-PD-NEC. Data from randomised trials are lacking
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Frizziero M
Authors: Frizziero M, Lamarca A, Kordatou Z, Barriuso J, Nuttall C,
Keywords: carboplatin-etoposide, poorly-differentiated extra-pulmonary neuroendocrine carcinoma, activity, efficacy, safety,
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,
Keywords: PDR001, immunotherapy, NET,